Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2 3Phase 1/2 3

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2Other hematologic neoplasm 2Thoracic 1Myeloid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 66Myelodysplastic Syndromes 38Leukemia, Myelomonocytic, Chronic 26Leukemia 14Myeloproliferative Disorders 10Recurrence 7Lymphoma 7Hematologic Neoplasms 7Neoplasms 6Primary Myelofibrosis 5Multiple Myeloma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm, Residual 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Glioblastoma 2Carcinoma, Renal Cell 2Anemia, Refractory, with Excess of Blasts 2

Interventions

Rituximab 56Cyclophosphamide 39fludarabine 23fludarabine phosphate 18Peripheral Blood Stem Cell Transplantation 17Lenalidomide 14Melphalan 13Etoposide 12venetoclax 11Whole-Body Irradiation 11Mycophenolic Acid 11obinutuzumab 10Vincristine 10Prednisone 10Bendamustine Hydrochloride 10Doxorubicin 9Cytarabine 9Cyclosporine 9Bortezomib 9Filgrastim 8pembrolizumab 7Nivolumab 7Gemcitabine 7Busulfan 7acalabrutinib 6Tacrolimus 6Interleukin-2 6Dexamethasone 6Carmustine 6Alemtuzumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Non-Hodgkin × Azacitidine × Clear all
NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

CellCentric Ltd.

Phase 1/2 Recruiting
250 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT01983969 2020-01-27

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
61 enrolled 10 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡